This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reed, J. C. Articles by Pleasure, D. Search for Related Content PubMed PubMed Citation Articles by Reed, J. C. Articles by Pleasure, D.

Differential Expression of bcl2 Protooncogene in Neuroblastoma and Other Human Tumor Cell Lines of Neural Origin¹

Department of Pathology and Laboratory Medicine, University of Pennsylvania [J. C. R., S. T., M. C., S. Y., C. G.], and Department of Neurology, Children's Hospital of Philadelphia [L. M., D. P.], Philadelphia, Pennsylvania 19104

The bcl2 protooncogene was originally discovered because of its involvement in t(14;18) chromosomal translocations frequently found in non-Hodgkin's lymphomas. The expression of this gene is reported to be highly tissue specific, with bcl2 mRNAs being readily detectable only in hematolymphoid tissues and brain. To explore the possible involvement of bcl2 in neural tumors, we surveyed a variety of tumor cell lines for the presence of the p26-BCL2 protein by immunoprecipitation and immunoblotting methods. Very high levels of BCL2 protein were found in three of nine neuroblastoma (NB) cell lines examined; these levels of p26-BCL2 were comparable to lymphoma cell lines that contain a t(14;18). Despite the impressive relative amounts of BCL2 protein, however, no structural alterations or changes in the methylation status of bcl2 genes were detected in these NB cell lines by conventional Southern blotting. Of the other NB cell lines surveyed, three contained intermediate levels of BCL2 and another three cell lines had little or no detectable BCL2 protein, raising the possibility that determination of relative levels of BCL2 protein may help to segregate neuroblastomas into groups with different biological and clinical characteristics. BCL2 protein levels were not influenced by induction of neuronal differentiation with nerve growth factor in two of the two cell lines examined [SH-SY5Y (high BCL2); GICAN (low BCL2)] and did not correlate with N-MYC gene amplification or expression of nerve growth factor receptors. NB cell lines that contained little or no detectable BCL2 protein, however, tended to contain significant proportions of flat epithelioid cells, whereas bcl2-expressing cell lines were composed primarily of neuronal-like cells, suggesting that expression of this protooncogene correlates with the differentiation characteristics of these tumor cell lines. In addition to NBs, lower levels of BCL2 protein were also found in a variety of other neural crest-derived tumors and tumor cell lines, including some neuroepitheliomas, Ewing's sarcomas, neurofibromas, and melanomas. With regard to tumors of central nervous system origin, bcl2 expression was absent from most medulloblastomas but was detected at moderate to low levels in a retinoblastoma and some glioblastoma multiforme cell lines. Taken together, these findings imply that bcl2 protooncogene expression is differentially regulated within the various lineages of cells that give rise to the nervous system.

¹ This work was supported by NIH Grants CA47956 and NS25044; ACS Grant CH460; and a Scholar Award (J. C. R.) from the Leukemia Society of America.

² To whom requests for reprints should be addressed.

Received 7/16/91. Accepted 10/ 7/91.

This article has been cited by other articles:

				K. A. Cole, E. F. Attiyeh, Y. P. Mosse, M. J. Laquaglia, S. J. Diskin, G. M. Brodeur, and J. M. Maris A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene Mol. Cancer Res., May 1, 2008; 6(5): 735 - 742. [Abstract] [Full Text] [PDF]

				A. Bevilacqua, M. C. Ceriani, G. Canti, L. Asnaghi, R. Gherzi, G. Brewer, L. Papucci, N. Schiavone, S. Capaccioli, and A. Nicolin Bcl-2 Protein Is Required for the Adenine/Uridine-rich Element (ARE)-dependent Degradation of Its Own Messenger J. Biol. Chem., June 20, 2003; 278(26): 23451 - 23459. [Abstract] [Full Text] [PDF]

				S. K. Cheema, S. K. Mishra, V. M. Rangnekar, A. M. Tari, R. Kumar, and G. Lopez-Berestein Par-4 Transcriptionally Regulates Bcl-2 through a WT1-binding Site on the bcl-2 Promoter J. Biol. Chem., May 23, 2003; 278(22): 19995 - 20005. [Abstract] [Full Text] [PDF]

				V. Poulaki, N. Mitsiades, M. E. Romero, and M. Tsokos Fas-mediated Apoptosis in Neuroblastoma Requires Mitochondrial Activation and Is Inhibited by FLICE Inhibitor Protein and bcl-2 Cancer Res., June 1, 2001; 61(12): 4864 - 4872. [Abstract] [Full Text] [PDF]

				D. A. Tweddle, A. J. Malcolm, M. Cole, A. D.J. Pearson, and J. Lunec p53 Cellular Localization and Function in Neuroblastoma : Evidence for Defective G1 Arrest Despite WAF1 Induction in MYCN-Amplified Cells Am. J. Pathol., June 1, 2001; 158(6): 2067 - 2077. [Abstract] [Full Text] [PDF]

				S. A. Gibson, C. Pellenz, R. E. Hutchison, F. R. Davey, and E. J. Shillitoe Induction of Apoptosis in Oral Cancer Cells by an Anti-bcl-2 Ribozyme Delivered by an Adenovirus Vector Clin. Cancer Res., January 1, 2000; 6(1): 213 - 222. [Abstract] [Full Text]

				J. M. Maris and K. K. Matthay Molecular Biology of Neuroblastoma J. Clin. Oncol., July 1, 1999; 17(7): 2264 - 2264. [Abstract] [Full Text] [PDF]

				V. Budhram-Mahadeo, P. J. Morris, M. D. Smith, C. A. Midgley, L. M. Boxer, and D. S. Latchman p53 Suppresses the Activation of the Bcl-2 Promoter by the Brn-3a POU Family Transcription Factor J. Biol. Chem., May 21, 1999; 274(21): 15237 - 15244. [Abstract] [Full Text] [PDF]

				Y. Kitamura, T. Kosaka, J.-I. Kakimura, Y. Matsuoka, Y. Kohno, Y. Nomura, and T. Taniguchi Protective Effects of the Antiparkinsonian Drugs Talipexole and Pramipexole against 1-Methyl-4-phenylpyridinium-Induced Apoptotic Death in Human Neuroblastoma SH-SY5Y Cells Mol. Pharmacol., December 1, 1998; 54(6): 1046 - 1054. [Abstract] [Full Text]

				B. A. Froesch, S. Takayama, and J. C. Reed BAG-1L Protein Enhances Androgen Receptor Function J. Biol. Chem., May 8, 1998; 273(19): 11660 - 11666. [Abstract] [Full Text] [PDF]

				D.-G. Wang, C. F. Johnston, J. J. Marley, K. V. Phenix, A. B. Atkinson, C. F. J. Russell, and K. D. Buchanan Expression of the Apoptosis-Suppressing Gene BCL-2 in Pheochromocytoma is Associated with the Expression of C-MYC J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1949 - 1952. [Abstract] [Full Text] [PDF]

				J. Diez, A. Panizo, M. Hernandez, and J. Pardo Is the Regulation of Apoptosis Altered in Smooth Muscle Cells of Adult Spontaneously Hypertensive Rats? Hypertension, March 1, 1997; 29(3): 776 - 780. [Abstract] [Full Text]

				N. Sakuragi, H. Matsuo, G. Coukos, E. E. Furth, M. P. Bronner, C. M. VanArsdale, S. Krajewsky, J. C. Reed, and J. F. Strauss Differentiation-Dependent Expression of the BCL-2 Proto-Oncogene in the Human Trophoblast Lineage Reproductive Sciences, April 1, 1994; 1(2): 164 - 172. [Abstract] [PDF]

				D. Merry, D. Veis, W. Hickey, and S. Korsmeyer bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS Development, January 2, 1994; 120(2): 301 - 311. [Abstract] [PDF]

				E. A. Lipscomb, P. D. Sarmiere, and R. S. Freeman SM-20 Is a Novel Mitochondrial Protein That Causes Caspase-dependent Cell Death in Nerve Growth Factor-dependent Neurons J. Biol. Chem., February 9, 2001; 276(7): 5085 - 5092. [Abstract] [Full Text] [PDF]